306 related articles for article (PubMed ID: 23957734)
21. Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis.
Zocco MA; dal Verme LZ; Cremonini F; Piscaglia AC; Nista EC; Candelli M; Novi M; Rigante D; Cazzato IA; Ojetti V; Armuzzi A; Gasbarrini G; Gasbarrini A
Aliment Pharmacol Ther; 2006 Jun; 23(11):1567-74. PubMed ID: 16696804
[TBL] [Abstract][Full Text] [Related]
22. Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.
Marteau P; Probert CS; Lindgren S; Gassul M; Tan TG; Dignass A; Befrits R; Midhagen G; Rademaker J; Foldager M
Gut; 2005 Jul; 54(7):960-5. PubMed ID: 15951542
[TBL] [Abstract][Full Text] [Related]
23. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.
Rembacken BJ; Snelling AM; Hawkey PM; Chalmers DM; Axon AT
Lancet; 1999 Aug; 354(9179):635-9. PubMed ID: 10466665
[TBL] [Abstract][Full Text] [Related]
24. Mesalazine and rifaximin in symptomatic uncomplicated diverticular disease.
Festi D; Colecchia A
Am J Gastroenterol; 2009 Feb; 104(2):532. PubMed ID: 19174809
[No Abstract] [Full Text] [Related]
25. Randomised controlled trial of mesalazine in IBS.
Barbara G; Cremon C; Annese V; Basilisco G; Bazzoli F; Bellini M; Benedetti A; Benini L; Bossa F; Buldrini P; Cicala M; Cuomo R; Germanà B; Molteni P; Neri M; Rodi M; Saggioro A; Scribano ML; Vecchi M; Zoli G; Corinaldesi R; Stanghellini V
Gut; 2016 Jan; 65(1):82-90. PubMed ID: 25533646
[TBL] [Abstract][Full Text] [Related]
26. Pathophysiology and Therapeutic Strategies for Symptomatic Uncomplicated Diverticular Disease of the Colon.
Scaioli E; Colecchia A; Marasco G; Schiumerini R; Festi D
Dig Dis Sci; 2016 Mar; 61(3):673-83. PubMed ID: 26458921
[TBL] [Abstract][Full Text] [Related]
27. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials.
Sandborn WJ; Kamm MA; Lichtenstein GR; Lyne A; Butler T; Joseph RE
Aliment Pharmacol Ther; 2007 Jul; 26(2):205-15. PubMed ID: 17593066
[TBL] [Abstract][Full Text] [Related]
28. A randomized controlled study of mesalamine after acute diverticulitis: results of the DIVA trial.
Stollman N; Magowan S; Shanahan F; Quigley EM;
J Clin Gastroenterol; 2013 Aug; 47(7):621-9. PubMed ID: 23426454
[TBL] [Abstract][Full Text] [Related]
29. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial.
Kruis W; Kiudelis G; Rácz I; Gorelov IA; Pokrotnieks J; Horynski M; Batovsky M; Kykal J; Boehm S; Greinwald R; Mueller R;
Gut; 2009 Feb; 58(2):233-40. PubMed ID: 18832520
[TBL] [Abstract][Full Text] [Related]
30. Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind placebo-controlled trial. The Italian IBD Study Group.
d'Albasio G; Paoluzi P; Campieri M; Bianchi Porro G; Pera A; Prantera C; Sturniolo GC; Miglioli M
Am J Gastroenterol; 1998 May; 93(5):799-803. PubMed ID: 9625131
[TBL] [Abstract][Full Text] [Related]
31. Balsalazide and/or high-potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon.
Tursi A; Brandimarte G; Giorgetti GM; Elisei W; Aiello F
Int J Colorectal Dis; 2007 Sep; 22(9):1103-8. PubMed ID: 17390144
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and Safety of Budesonide, vs Mesalazine or Placebo, as Induction Therapy for Lymphocytic Colitis.
Miehlke S; Aust D; Mihaly E; Armerding P; Böhm G; Bonderup O; Fernández-Bañares F; Kupcinskas J; Munck LK; Rehbehn KU; Nacak T; Greinwald R; Münch A;
Gastroenterology; 2018 Dec; 155(6):1795-1804.e3. PubMed ID: 30195447
[TBL] [Abstract][Full Text] [Related]
33. Is mesalazine treatment effective in the prevention of diverticulitis? A review.
Stefanelli G; Viscido A; Valvano M; Vernia F; Frieri G; Ashktorab H; Latella G
Eur Rev Med Pharmacol Sci; 2020 Aug; 24(15):8164-8176. PubMed ID: 32767345
[TBL] [Abstract][Full Text] [Related]
34. Prevention of relapse by mesalazine (Pentasa) in pediatric Crohn's disease: a multicenter, double-blind, randomized, placebo-controlled trial.
Cezard JP; Munck A; Mouterde O; Morali A; Lenaerts C; Lachaux A; Turck D; Schmitz J; Maurage C; Girardet JP; Belli D; Lamireau T; Sarles J; Chouraqui JP; Descos B; Dabadi A; Meyer M; Olives JP; Mary JY
Gastroenterol Clin Biol; 2009 Jan; 33(1 Pt 1):31-40. PubMed ID: 19118966
[TBL] [Abstract][Full Text] [Related]
35. High-fibre diet and Lactobacillus paracasei B21060 in symptomatic uncomplicated diverticular disease.
Lahner E; Esposito G; Zullo A; Hassan C; Cannaviello C; Paolo MC; Pallotta L; Garbagna N; Grossi E; Annibale B
World J Gastroenterol; 2012 Nov; 18(41):5918-24. PubMed ID: 23139608
[TBL] [Abstract][Full Text] [Related]
36. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine.
Kruis W; Fric P; Pokrotnieks J; Lukás M; Fixa B; Kascák M; Kamm MA; Weismueller J; Beglinger C; Stolte M; Wolff C; Schulze J
Gut; 2004 Nov; 53(11):1617-23. PubMed ID: 15479682
[TBL] [Abstract][Full Text] [Related]
37. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial.
Reinisch W; Angelberger S; Petritsch W; Shonova O; Lukas M; Bar-Meir S; Teml A; Schaeffeler E; Schwab M; Dilger K; Greinwald R; Mueller R; Stange EF; Herrlinger KR;
Gut; 2010 Jun; 59(6):752-9. PubMed ID: 20551460
[TBL] [Abstract][Full Text] [Related]
38. Combination therapy with symbiotics and local anti-inflammatories for red anusitis.
Cafaro D; Onofrio L; D'Agostino G
Minerva Gastroenterol Dietol; 2007 Jun; 53(2):117-23. PubMed ID: 17557039
[TBL] [Abstract][Full Text] [Related]
39. Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials.
Lichtenstein GR; Zakko S; Gordon GL; Murthy U; Sedghi S; Pruitt R; Merchant K; Bortey E; Forbes WP
Aliment Pharmacol Ther; 2012 Jul; 36(2):126-34. PubMed ID: 22617015
[TBL] [Abstract][Full Text] [Related]
40. 3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial.
Gross V; Bunganic I; Belousova EA; Mikhailova TL; Kupcinskas L; Kiudelis G; Tulassay Z; Gabalec L; Dorofeyev AE; Derova J; Dilger K; Greinwald R; Mueller R;
J Crohns Colitis; 2011 Apr; 5(2):129-38. PubMed ID: 21453882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
